Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
; 37(3): 420, 2020 Mar 16.
Article
in En
| MEDLINE
| ID: mdl-32183953
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2020
Document type:
Article